leading innovation in pain & inflammation...this presentation contains forward-looking...

Leading Innovation in Pain & InflammationI N V E S T O R P R E S E N T A T I O N

MAY 2020

Antibe Therapeutics Inc. www.antibethera.com May 2020 2

This presentation contains forward-looking information and statements which constitute “forward-looking information” under Canadian securities law and which may be material regarding, among other things, the Company’s beliefs, plans, objectives, estimates, intentions and expectations. Specific forward-looking information in this document includes, but is not limited to, statements with respect to the Company’s future operating and financial results, its research and development activities, its capital expenditure plans and the ability to execute on its future operating, investing and financing strategies. These forward-looking information and statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. We consider the assumptions on which these forward-looking statements are based to be reasonable, but caution the reader that these assumptions regarding future events, many of which are beyond our control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect us. Additional information regarding risk factors can be found in public disclosure records on SEDAR.

Our statements of “belief” in respect of our product and partner product candidates are based primarily upon our results derived to date from our research and development program. We believe that we have a reasonable scientific basis upon which we have made such statements. It is not possible, however, to predict, based upon in vitro and animal studies whether a new therapeutic agent or technology will be proved to be safe and/or effective in humans. We cannot assure that the particular results expected by us will occur.

Any forward-looking statements and statements of “belief” represent our estimates only and should not be relied upon as representing our estimates as of any subsequent date. Except as required by law, we do not assume any obligation to update any forward looking statements or statements of “belief”. We disclaim any intention or obligation to update or revise any forward- looking statements or statements of “belief”, whether as a result of new information, future events or otherwise. Nothing herein should be construed as an Offering of securities of the Company in any jurisdictions.

Forward-Looking Statements

Antibe is on the verge of solving one of the most pervasive medical problems of our time.


Nonsteroidal anti-inflammatory drugs (“NSAIDs”) are among the most widely used medications in the world, yet they are associated with severe gastrointestinal (“GI”) ulceration and bleeding.

NSAIDs: A Massive Market Opportunity

GIA Global

Unmet Need

Damage is Pervasive

Global Market for NSAIDs1

$11 Billion

1) Global sales in 2014 (Evaluate Pharma).


Of the sixteen drugs which hit $1 billion in sales in their first year, two were designed to address the GI-toxicity issue with NSAIDs.

NSAIDs Have a Blockbuster Pedigree

Product CompanyTherapeutic

CategoryUS Sales in First Year

Harvoni Gilead Hep C Antiviral $10.6B

Sovaldi Gilead Hep C Antiviral $9.0B

Epclusa Gilead Hep C Antiviral $3.2

Celebrex Pharmacia NSAID $2.3B

Olysio J&J Hep C Antiviral $2.1B

Tecfidera Biogen MS $1.8B

Incivek Vertex Hep C Antiviral $1.7B

Ocrevus Roche MS $1.7B

Lipitor Pfizer Statin $1.5B

Vioxx Merck & Co NSAID $1.5B

Source: Evaluate Pharma (top ten shown).


ATB-346 was designed to deliver both GI and cardiovascular safety with non-addictive pain relief.

Addressing an Unmet Need…

Better GI Safety

Better CV Safety

ATB-346

Naproxen

Non-selective NSAIDs

The Need

Vioxx

Celebrex

Meloxicam

Several selective COX-2 NSAIDs were withdrawn or

discontinued due to increased risk of CV events1

BextraWITHDRAWN

WITHDRAWN

1. Source: FDA. Postmarket Drug Safety Information for Patients and Providers (Voluntarily Withdrawal of Vioxx, Sept/04 and FDA Request for Withdrawal of Bextra, April/05).

Schematic for illustrative purposes – not to scale

ATB-346: Lead Drug


• Novel anti-inflammatory drug that releases hydrogen sulfide (“H2S”)

• Negligible GI damage: greatly superior to existing NSAIDs

• No significant effect on blood pressure, unlike existing NSAIDs

• Global IP and exclusivity with market protection in US to ~2031 (EU to 2033) - Patents granted in major markets (including US, Europe, Japan, China & Canada)

Our Lead Drug: ATB-346


Hydrogen sulfide (“H2S”) has become recognized as a crucial signalling molecule with a wide range of anti-inflammatory and cytoprotective functions.

H2S: Anti-inflammatory & Cytoprotective

Nature Reviews | Drug Discovery

Analgesic

Rolling

Adhesion

r�+PJKDKVU�NGWMQE[VGs��GPFQVJGNKCN�EGNN�CFJGUKQPr�4GFWEGU�QGFGOC�HQTOCVKQP

#62�IGPGTCVKQP

ATP

2TQ�KPȯCOOCVQT[E[VQMKPGU

NF!$�

O40#

"NF!$�CEVKXCVKQP

Antioxidant

H2Se e e

ee

eeeee e e

eee

e

M1 M2

H2S

4GUQNWVKQP�QH�KPȯCOOCVKQP�

H2S

NRF2

NRF2

KEAP1

NRF2 MAF

ARE

6TCPUETKRVKQPCNN[CEVKXG�EQORNGZ

GeneVTCPUETKRVKQP

DissociationHTQO�-'#2�

H2S04(�s-'#2�RCVJYC[�

*[FTQIGP�UWNRJKFG

0GWVTQRJKN�CRQRVQUKU

4GRCKT

Vasodilation

PDE

Source: Wallace & Wang, Nature Reviews Drug Discovery 2015; 14,329-345.


1) Source (left): Wallace & Wang, Nature Reviews Drug Discovery 2015; 14,329-345. 2) Source (right): Gemici et al., Nitric Oxide 46 (2015) 25–31.

• H2S physiological activities reduce inflammation in the gastrointestinal (“GI”) tract and prevent NSAID-induced injury

H2S Prevents NSAID-Induced Injury

Antibe Therapeutics Inc. www.antibethera.com May 2020

Gastric ulcer incidence of ATB-346 (>=3mm diameter) versus naproxen during two-week

treatment period

# of

Sub

ject

s tha

t Dev

elop

ed U

lcer

s

0

15

30

45

60

ATB-346 Naproxen

11

• A successful Phase 2B double blind GI safety study for ATB-346 was completed in March 2018 in 244 healthy volunteers

• Validation of GI safety superiority: ATB-346 exhibited an ulceration rate of 2.5% versus 42.1% for naproxen over the two-week treatment period (p<0.0001)

• ATB-346 was safe and well-tolerated

Strong Phase 2B GI Safety Data

42.1%

2.5%

(n = 118) (n = 126)


• Strong secondary endpoint data

• Gastroduodenal ulcers and erosions - Total number of ulcers ≥3 mm: 4 for ATB-346 vs 210 for naproxen

- Large ≥5 mm ulcer incidence: 0% for ATB-346 vs 24% for naproxen

- Mean erosions per subject: 1.7 for ATB-346 vs 12.7 for naproxen

• Non-GI secondary endpoints and overall safety - Thromboxane (TXB2) inhibition for ATB-346 was not statistically

different than naproxen

- No blood pressure increases for ATB-346

- Safe and well tolerated: overall very low incidence of adverse events for ATB-346

Strong Phase 2B GI Safety Data cont’d

Total number of GI ulcers (>= 3mm diameter)

Num

ber o

f Ulc

ers

0

60

120

180

240

ATB-346 Naproxen

Incidence of large GI ulcers (>=5mm diameter)

Ulc

er In

cide

nce

0%

10%

20%

30%

40%

ATB-346 Naproxen

COX inhibition

TXB2

Syn

thes

is (p

g/m

L)

0

25

50

75

100

Day 0 Day 7 Day 14

ATB-346Naproxen

24%

0%

203

4


(1) Boucher, Martin. A Bayesian Meta-Analysis of Longitudinal Data in Placebo Controlled Studies with Naproxen. Pfizer. (2) Wittenburg et al. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib. Arthritis Research & Therapy Vol 8 No 2 (2004).

• Phase 2B dose-ranging, efficacy study for ATB-346 designed to validate efficacy in reducing pain and establish the Phase 3 dose

• 360 osteoarthritis patients are being randomized to either placebo or one of three doses of ATB-346 (150 mg, 200 mg or 250 mg) once daily

• A total of 40 clinical sites — the largest number of sites for any clinical trial ever conducted in Canada

• Top-line data expected in June 2020

Final Phase 2 Study Underway

Earlier Phase 2A Efficacy Study Results (completed in August 2016)

Current Phase 2B study is looking to replicate the success of the Phase 2A efficacy study

completed in 2016.

Change of Pain Severity in OA patients treated once daily with

250 mg of ATB-346

Mea

n W

OM

AC P

ain

Scor

e △

-10

-8

-6

-4

-2

0

Day -1 Day 4 Day 10

Average pain reduction with celecoxib or naproxen (twice daily)1,2

n = 12

H2S Platform: Other Pipeline Drugs


• Antibe has commenced IND-enabling pre-clinical studies for ATB-352, a potent and non-addictive analgesic for severe pain to address the global opioid crisis

• Post-operative pain has been identified as the lead indication, a US$9 billion market opportunity1

ATB-352: Addressing the Opioid Crisis…

Every day, over 1,000 people are treated in emergency departments for misusing prescription opioids.

“”

- US Department of Health and Human Services (2013)

0

6,000

12,000

18,000

24,000

1999 2001 2003 2005 2007 2009 2011 2013 2015

NUMBER OF DEATHS FROM OPIOID PAIN RELIEVERS*

*United States, including non-methadone synthetics (fentanyl)2

1) 2019 estimate based on US$5.9B 2010 estimate and 5.3% annual growth rate (BioPharm Insight) 2) Source: National Center on Health Statistics, CDC Wonder


ATB-352 causes negligible GI damage in rats compared to ketoprofen, a very strong NSAID prescribed for acute pain.

ATB-352: Potent Analgesic for Acute Pain

Source: Nitric Oxide 2014 159, 1236-1246. *rat study


• Low-dose aspirin has been known for decades to provide a dramatic reduction in the risk of stroke and, more recently, a reduction in the risk of digestive system cancers

• However, aspirin, like other NSAIDs, causes stomach ulcers and GI bleeding in an appreciable portion of the population which precludes its broad prescription by physicians

• ATB-340 is a H2S-releasing derivative of aspirin that has been shown to be GI-safe in pre-clinical studies

ATB-340: A Drug for Everyone Over 50?


Aspirin, but not ATB-340, causes significant gastric erosions in the rat stomach.

ATB-340: Low-Dose Aspirin Derivative

Source: Gemici et al., Nitric Oxide 46 (2015) 25–31.*rat study

Citagenix: Commercial Asset in Regenerative Medicine


• Our commercial subsidiary, Citagenix Inc. (“Citagenix”), is the market leader in Canada in dental regenerative medicine and is now growing well in the United States

Citagenix: Poised for Global Growth…

FO-162

TASO-9

BS-61

TASO-8

MPI-1

TASO-7

TASO-6

TASO-5

TASO-4

IM-15

USB-P3

SS-65

TASO-3

TASO-2

TASO-1

MA-2SM-15 SM-21 707-23D1707-2N COLLEGE

RH-4

BS-59

MA-B1 BD-158

IM-15 OBN-4

100-C15

718-107

MIR-08

MO-10

PH-79

FG-2SCZFG-1SCZ

BS-60SS-65

BD-30

100-C15MA-B1

BD-158

707-2311LS-08

BD-30

ES-13

LB-369

LB-367

LB-364

BB-46

FD-170

FG-1SCZ

FG-2SCZ

BS-60

Instrument Kits

Instruments withTungsten-CarbideInserts

Instruments withExtremely Sharp Razor Edge Atraumatic

Scissors withOne side serrated

GUIDED BONE— REGENERATION KIT —

BMTGUIDED TISSUE— REGENERATION KIT —

BMT

BD-30 Tissue Forceps MA-B1 Scalpel handle

LS-08 Ruler ES-13 Dissector

100-C15 Scalpel blades 707-2311 Double-ended explorer

FG-1SCZ Iris Super-Cut scissors, Straight BS-60 Tray for 10 instruments

FG-2SCZ Iris Super-Cut scissors, Curved FD-170 Needle holder

BB-46 Micro scalpel handle BD-158 Micro suture and membrane forceps

LB-364, 367, 369 Micro blades

SINUS LIFT— SURGERY KIT —

BMT

TASO-9 Membrane placement forceps TASO-1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | Sinus lift instruments

FO-162 Bone forceps for opening the sinus IM-15 Bone Material Applicator

SS-65 Stainless steel bone well, Ø 35 mm MPI-1 Membrane Placement Instrument

BS-61 Tray for 20 instruments USB-P3 Bone grafting packer

COLLEGE Dressing forceps 707-2N Double-ended periodontal probe

SM-15 Periodontal probe 707-23D1 Double-ended explorer / probe

SM-21 Periodontal probe BS-59 Tray for 5 instruments

MA-2 Mirror handle

PERIODONTAL— EXAM KIT —

BMT

SHARP

SHARP

SHARP

TUNGSTENCARBIDE

SERRATED

TUNGSTENCARBIDE

SERRATED

PH-79 Needle Holder, 145 mm MO-10 Surgical Curette

FG-1SCZ Iris Super-Cut scissors, Straight MIR-08 Periosteal Raspatory

FG-2SCZ Iris Super-Cut scissors, Curved 718-107 Periodontal Chisel

100-C15 Scalpel Blades OBN-4 Gingivectomy Knives

SS-65 Stainless steel bone well, Ø 35 mm BD-158 Micro Suture and Membrane Forceps

MA-B1 #5 Scalpel Handle BD-30 Tissue Forceps IM-15 Applicator for Bone Material BS-60 Tray for 10 instruments

BLUNT

SHARP

SHARP

SHARP

BLUNT

SHARP

SHARP

SHARP

17

Bone Graft Substitutes

Dental Barrier Membranes

High Quality Instruments

Global Market for Oral Tissue Regeneration2

US$700 MILLION

Citagenix has a $10M1 revenue base and has initiated a global growth strategy

Regenerative medicine is growing globally at 30%+3

DBM RPM

ABM

Bone Graft Substitutes

Demineralized bone matrix with cancellous boneDynaBlast™ is a composite graft product that combines osteoinductive and osteoconductive elements in a proprietary, reverse phase medium for superior handling.

Demineralized bone matrixDynaGraft·D™ is a !rst generation demineralized bone matrix in a reverse phase medium for superior handling.

DynaGraft·D™ 0.5 cc syringe - (gel) 10-110-10501 cc syringe - (gel) 10-110-10601 cc jar - (putty) 10-120-10502.5 cc jar - (putty) 10-120-1060

Applications

DynaGraft·D• Periodontal defects• Extraction site repair• Implant site development• Sinus lift procedures• Coronal defects around immediate implants

DBM RPM

DynaBlast™ 0.5 cc syringe - (paste) 10-210-10501 cc syringe - (paste) 10-210-10603 cc syringe - (paste) 10-210-10701 cc jar - (putty) 10-220-10302.5 cc jar - (putty) 10-220-1040

Applications

DynaBlast• Extraction site repair• Implant dehiscence defects• Sinus lift procedures• Moderate localized ridge defects

DBM RPM

CANCELLOUS

Demineralized bone matrix puttyAccell Connexus is a high surface area demineralized bone matrix (ABM) that incorporates a highly biocompatible Reverse Phase Medium (RPM) for robust handling.

Accell Connexus® 0.5 cc syringe - (putty) 10-310-10501 cc syringe - (putty) 10-310-1060

Applications Accell Connexus

• When the highest level of growth factors is desired• Osseous defects• In combination with less osteoinductive materials• Implant site preparation or repair

Features & Bene!ts• Highest osteoinductive potential • RPM thickens at body temperature• Resists irrigation• Ready to use

Synthetic resorbable bone substituteSynthetic resorbable bone substitute that uses the mineral building blocks naturally found in human bone. Eclipse™ goes a step beyond with its unique combination of micro and macroporosity technology.

Granules: 80% ß-tcp - 20% HA — Putty: 40% ß-tcp - 60% HA

Applications• Ridge preservation• Extraction site repair• Sinus lifts• Ridge augmentation• Osseous defects• Periodontal defects

Eclipse™May be used alone or mixed with DBM

Putty for osteoinductive potential.

Eclipse™ Granules 0.5 to 1.0 mm0.25 cc (vial) E1G0020.5 cc (vial) E1G0051 cc (vial) E1G0100.5 cc (syringe) E1GS0051.0 cc (2 x 0.5 cc syringes in a single sterile package) E1GS010

Eclipse™ Granules 1.0 to 2.0 mm 2.0 cc (vial) E2G020

Eclipse™ Putty 40 | 60 0.5 cc (syringe) E1P0051.0 cc (2 x 0.5cc syringes in separate sterile packages) E1P010

71) Annual run rate based on the nine month period ended December 31, 2019 2) Source: Straumann 2016 Annual Report (page 53) assuming USD:CHF FX rate of 1.00 : 1.00 3) Source: BCC Research LLC, September 2016

Corporate Information


• Dan Legault JD CHIEF EXECUTIVE OFFICER

• John Wallace PhD, MBA CHIEF SCIENTIFIC OFFICER

• Joseph Stauffer DO, MBA CHIEF MEDICAL OFFICER

• David Vaughan PhD CHIEF DEVELOPMENT OFFICER

• Alain Wilson MBA CHIEF FINANCIAL OFFICER

• Scott Curtis MEng, CFA EXECUTIVE VP

• Rami Batal PhD, MBA SENIOR VP, COMMERCIAL STRATEGY

Management & Board of Directors

Management Board of Directors• Walt Macnee MBA Chairman

VICE CHAIRMAN / MASTERCARD INC.

• Roderick Flower PhD EMERITUS PROFESSOR OF PHARMACOLOGY / WILLIAM HARVEY RESEARCH INSTITUTE (WHRI)

• Amal Khouri MBA VP, BUSINESS DEVELOPMENT / KNIGHT THERAPEUTICS INC.

• Dan Legault JD CHIEF EXECUTIVE OFFICER

• John Wallace PhD, MBA CHIEF SCIENTIFIC OFFICER

• Yung Wu CHIEF EXECUTIVE OFFICER / MARS DISCOVERY DISTRICT


Our clinical and scientific advisory boards are comprised of world-class scientists, including a Nobel Laureate.

World-Class Scientific Advisors

• Dr. Andre Buret PhD CALGARY, ALBERTA

• Dr. Francis Chan MD, PhD HONG KONG, CHINA

• Dr. Giuseppe Cirino PhD NAPLES, ITALY

• Dr. Peter B. Ernst DVM, PhD SAN DIEGO, CALIFORNIA

• Dr. Derek Gilroy PhD LONDON, ENGLAND

• Dr. Richard H. Hunt MD OXFORD, ENGLAND

• Dr. Louis J. Ignarro PhD LOS ANGELES, CALIFORNIA

• Dr. Angel Lanas MD, DSc ZARAGOZA, SPAIN

• Dr. Gilberto de Nucci MD, PhD SAO PAOLO, BRAZIL

• Dr. Daniel K. Podolsky MD DALLAS, TEXAS

• Dr. James Scheiman BS, MD ANN ARBOR, MICHIGAN

• Dr. William Sessa PhD NEW HAVEN, CONNECTICUT

• Dr. Philip M. Sherman MD TORONTO, ONTARIO

• Dr. J. Carter Thorne MD, FRCP(C), FACP NEWMARKET, ONTARIO


• Angus Russell CA

- Former CEO of Shire (2008 - 2013) — led expansion into new therapeutic areas through a series of late-stage deals

- Currently Chairman of Mallinckrodt, a leading global specialty pharma company

• Dominique Monnet MBA

- Responsible for accelerating growth of Amgen’s Inflammation division and its Enbrel® franchise

- Currently President of PDL BioPharma, a manager of healthcare companies, products and royalties

• Andrew Powell JD

- Played instrumental role in the sale of: Medivation to Pfizer for US$14B; InterMune to Roche for US$8.3B; ImClone to Eli Lilly for US$6.5B

- Currently a director at Aclaris Therapeutics, a biopharma company focused on dermatology

Partnering Advisory Team


Capitalization Summary

Stock Symbols TSXV-ATE; OTCQB-ATBPF

Share Price(1) $0.68

Shares Outstanding 301M

Stock Options & RSUs 42M

Warrants 21M

Market Capitalization(1) $205M

Cash & Equivalents(2) $6M

Insider Ownership FULLY DILUTED 19%

Annual Sales(3) $10M

1) As of market close May 5, 2020 2) As of May 1, 2020 (disclosed in May 4, 2020 press release) 3) Annual run rate based on the nine month period ended December 31, 2019

Volu

me

(mill

ions

)

1

2

3

4

5

Shar

e Pr

ice

(CAD

)

$0.10

$0.20

$0.30

$0.40

$0.50

$0.60

$0.70

$0.80

May-19 Jun-19 Aug-19 Sep-19 Nov-19 Dec-19 Jan-20 Mar-20 Apr-20


• Best-in-class drug platform: Antibe’s proprietary hydrogen sulfide (“H2S”) technology represents a major medical advance in the safe treatment of pain & inflammation

• Strong Phase 2 proof-of-concept data: Antibe’s lead drug, ATB-346, recently showed unequivocal superiority to naproxen in GI safety (2.5% versus 42.1% ulceration rate)

• Phase 2 dose-ranging, efficacy study underway: will provide a robust package of efficacy and metabolism data for regulatory bodies and global partners

• Potential to disrupt global pain market: the global pain market, including opioids, exceeds $20 billion and would benefit greatly from GI-safe and non-addictive therapies

• Commercial asset in regenerative medicine: Antibe’s subsidiary, Citagenix, is poised for growth in the dental biologics market with a revenue base of $10 million1

• Seasoned management team, Board of Directors and advisors

Key Takeaways

1) Annual run rate based on the nine month period ended December 31, 2019

Thank You.

ANTIBE THERAPEUTICS INC.

15 Prince Arthur Avenue, Toronto, ON M5R 1B2

+1 416 – 473 – 4095

antibethera.com

TSXV: ATE

OTCQB: ATBPF

leading innovation in pain & inflammation...this presentation contains forward-looking...

Documents